

**Ojjaara**  
(mometinib)  
200 mg • 150 mg • 100 mg tablets

## Talking to your doctor about OJJAARA



Not an actual doctor or patient.

### This guide may be helpful for your next visit with your healthcare team

OJJAARA is the first and only FDA-approved treatment specifically for adults with certain types of myelofibrosis who have anemia. It is not known if OJJAARA is safe and effective in children.

Living with myelofibrosis with anemia may feel overwhelming at times. This guide includes questions and topics you may find useful when talking to your doctor. **You can also print this guide and bring it with you to appointments, so you can refer to it and take notes.**

### APPROVED USE

OJJAARA is a prescription medicine used to treat adults with certain types of myelofibrosis (MF) who have anemia. It is not known if OJJAARA is safe and effective in children.

### IMPORTANT SAFETY INFORMATION

**OJJAARA may cause serious side effects, including:**

- **Risk of Infections.** People who take OJJAARA may develop serious infections that can lead to death, such as bacterial and viral infections, including COVID-19. If you have an active infection, your healthcare provider should not start treatment with OJJAARA until your infection is gone. If you have had hepatitis B for a long time (chronic), OJJAARA may cause your hepatitis B to become active again, and your healthcare provider will check your blood for active hepatitis B before starting treatment. Your healthcare provider will monitor you and treat you for any infections that you get during treatment with OJJAARA. **Tell your healthcare provider right away if you develop any of the following symptoms of infection:**

- fever
- chills
- cough
- breathing problems
- diarrhea
- vomiting
- pain or burning feeling when passing urine

**Please see additional Important Safety Information throughout and on page 5.**

**Please see full Prescribing Information, including Patient Information.**

# Myelofibrosis with anemia care: Keep an eye on your symptoms

It is important to update your healthcare team on how your myelofibrosis with anemia symptoms may be affecting you and if you are experiencing any changes in your myelofibrosis symptoms. You can use this page to help keep track of your symptoms, how often they occur, and any details or notes that may help your healthcare team understand how you are affected by your myelofibrosis with anemia. **Check the circle next to each symptom that applies to you.**

To download an expanded month-by-month version of this tracker, visit [OJJAARA Resources](#).

Day	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
Date							
Symptom	This is not a complete list of all possible myelofibrosis with anemia symptoms, and OJJAARA may not help with all of these symptoms. If you're experiencing severe symptoms that require medical attention, please contact your physician immediately.						
Fatigue	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never
Tiredness	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never
Feeling full too quickly	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never
Pain under ribs on left side	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never
Abdominal discomfort	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never
Night sweats	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never
Itching	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never
Bone pain	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never	<input type="radio"/> Often <input type="radio"/> Sometimes <input type="radio"/> Never

**Print and bring this list to your next doctor's visit, and discuss your symptoms with your healthcare team. You can use the notes section on the next page to write down any other symptoms you may be feeling that are different from those already listed.**

## IMPORTANT SAFETY INFORMATION (cont'd)

- **Low platelet and white blood cell counts.** OJJAARA may cause new or worsening low platelet and white blood cell counts. Low platelet counts may increase your risk for bleeding and low white blood cell counts may increase your risk for infection. Your healthcare provider will do blood tests to check your blood counts before you start taking OJJAARA and during treatment. Tell your healthcare provider right away if you have any signs of bleeding during treatment with OJJAARA, including:
  - unusual bleeding
  - black or tarry stools
  - bruising

**Please see additional Important Safety Information throughout and on page 5.  
Please see full Prescribing Information, including Patient Information.**



# Identify your myelofibrosis with anemia treatment goals

Myelofibrosis with anemia can affect people differently. That’s why it’s important to work with your healthcare team to determine your unique treatment goals.

**Below are examples of things you can discuss with your doctor when talking about your treatment goals.**

## “I want to know...”

- More about the treatment options for myelofibrosis with anemia
- Whether my myelofibrosis with anemia symptoms can be managed
- More about my blood transfusion plan, if I need it
- How often I should come in for my checkups/appointments
- About any healthy lifestyle changes I can make
- How you’ll track my progress toward my treatment goals



## NOTES

---

---

---

---

---

---

---

---

---

---



### **BE YOUR OWN ADVOCATE; SPEAK UP!**

Having open conversations with your doctor is important. It’s an opportunity to share symptoms and get answers to your questions.

## **IMPORTANT SAFETY INFORMATION (cont’d)**

- **Liver problems.** OJJAARA may cause new or worsening increased liver enzymes and bilirubin in your blood. Your healthcare provider will check your liver enzymes before starting treatment, every month for the first 6 months of treatment, and then as needed during treatment with OJJAARA. Your healthcare provider may stop treatment with OJJAARA if your liver enzymes increase. Tell your healthcare provider if you develop any of the following signs or symptoms of liver problems:
  - tiredness
  - loss of appetite
  - pain in your right upper stomach area (abdomen)
  - dark urine
  - yellowing of your skin or the white part of your eyes

**Please see additional Important Safety Information throughout and on page 5.  
Please see full Prescribing Information, including Patient Information.**



# Questions to ask your healthcare team about OJJAARA

You may have questions about your myelofibrosis with anemia treatment options. Below are some conversation starters you could use when talking to your doctor.

Use the notes section to write down any additional thoughts you may have or important topics you want to remember during your visit.

Do you think **OJJAARA** may be right for me? Why or why not?

What **laboratory tests** would be needed when taking OJJAARA?

What type of **medicine** is OJJAARA, and how does it work?

What kind of **results** might I expect with OJJAARA?

How might OJJAARA **interact** with any of my other medicines?

What are the possible **side effects** of OJJAARA?

How might OJJAARA **fit into** my medication schedule?

Write your own question here to bring with you to your next appointment.

## NOTES

## IMPORTANT SAFETY INFORMATION (cont'd)

- **Major cardiovascular events such as heart attack, stroke, and death.** Major cardiac events have happened, especially in people with cardiac risk factors and who are current or past smokers, taking another Janus kinase (JAK) inhibitor to treat rheumatoid arthritis. OJJAARA is in the JAK family of medicines. **Get emergency help right away if you have any symptoms of a heart attack or stroke while taking OJJAARA, including:**
  - discomfort in your chest that lasts for more than a few minutes, or that goes away and comes back
  - severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  - pain or discomfort in your arms, back, neck, jaw, or stomach
  - shortness of breath with or without chest discomfort
  - breaking out in a cold sweat
  - nausea or vomiting
  - feeling lightheaded
  - weakness in one part or on one side of your body
  - slurred speech

**Please see additional Important Safety Information throughout and on page 5.  
Please see full Prescribing Information, including Patient Information.**

**Ojjaara**  
(momelotinib)

## APPROVED USE

OJJAARA is a prescription medicine used to treat adults with certain types of myelofibrosis (MF) who have anemia. It is not known if OJJAARA is safe and effective in children.

## IMPORTANT SAFETY INFORMATION

**OJJAARA may cause serious side effects, including:**

• **Risk of Infections.** People who take OJJAARA may develop serious infections that can lead to death, such as bacterial and viral infections, including COVID-19. If you have an active infection, your healthcare provider should not start treatment with OJJAARA until your infection is gone. If you have had hepatitis B for a long time (chronic), OJJAARA may cause your hepatitis B to become active again, and your healthcare provider will check your blood for active hepatitis B before starting treatment. Your healthcare provider will monitor you and treat you for any infections that you get during treatment with OJJAARA.

**Tell your healthcare provider right away if you develop any of the following symptoms of infection:**

- fever
- chills
- cough
- breathing problems
- diarrhea
- vomiting
- pain or burning feeling when passing urine

• **Low platelet and white blood cell counts.** OJJAARA may cause new or worsening low platelet and white blood cell counts. Low platelet counts may increase your risk for bleeding and low white blood cell counts may increase your risk for infection. Your healthcare provider will do blood tests to check your blood counts before you start taking OJJAARA and during treatment. Tell your healthcare provider right away if you have any signs of bleeding during treatment with OJJAARA, including:

- unusual bleeding
- black or tarry stools
- bruising

• **Liver problems.** OJJAARA may cause new or worsening increased liver enzymes and bilirubin in your blood. Your healthcare provider will check your liver enzymes before starting treatment, every month for the first 6 months of treatment, and then as needed during treatment with OJJAARA. Your healthcare provider may stop treatment with OJJAARA if your liver enzymes increase. Tell your healthcare provider if you develop any of the following signs or symptoms of liver problems:

- tiredness
- loss of appetite
- pain in your right upper stomach area (abdomen)
- dark urine
- yellowing of your skin or the white part of your eyes

• **Major cardiovascular events such as heart attack, stroke, and death.** Major cardiac events have happened, especially in people with cardiac risk factors and who are current or past smokers, taking another Janus kinase (JAK) inhibitor to treat rheumatoid arthritis. OJJAARA is in the JAK family of medicines. **Get emergency help right away if you have any symptoms of a heart attack or stroke while taking OJJAARA, including:**

- discomfort in your chest that lasts for more than a few minutes, or that goes away and comes back
- severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
- pain or discomfort in your arms, back, neck, jaw, or stomach
- shortness of breath with or without chest discomfort

- breaking out in a cold sweat
- nausea or vomiting
- feeling lightheaded
- weakness in one part or on one side of your body
- slurred speech

• **Blood clots.** Blood clots in the veins of the legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in some people taking another JAK inhibitor to treat rheumatoid arthritis, and may be life-threatening. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past.

**Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OJJAARA, including:**

- swelling, pain, or tenderness in one or both legs
- sudden, unexplained chest pain
- shortness of breath or difficulty breathing

• **New cancers.** New cancers, including lymphoma and other cancers, except non-melanoma skin cancer, have happened in some people taking another JAK inhibitor to treat rheumatoid arthritis. The risk of new cancers is further increased in people who smoke or who smoked in the past.

**The most common side effects of OJJAARA include:**

- low platelet count
- bleeding
- bacterial infection
- tiredness
- dizziness
- diarrhea
- nausea

These are not all the possible side effects of OJJAARA. Call your doctor for medical advice about side effects.

**Before taking OJJAARA, tell your healthcare provider about all your medical conditions, including if you:**

- have an infection
- have or have had hepatitis B
- have or have had liver problems
- have had a heart attack, or have or have had other heart problems, or stroke
- have or have had a blood clot
- smoke or were a smoker in the past
- have or have had any other cancers
- are pregnant or plan to become pregnant. OJJAARA may harm your unborn baby.

**Females who are able to become pregnant:**

- You should use effective birth control (contraception) during treatment and for 1 week after the last dose of OJJAARA.
- Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with OJJAARA.
- are breastfeeding or plan to breastfeed. It is not known if OJJAARA passes into your breast milk. You should not breastfeed during treatment and for 1 week after the last dose of OJJAARA. Talk to your healthcare provider about the best way to feed your baby during this time.

**Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking OJJAARA with certain other medicines may affect the amount of OJJAARA or the other medicines in your blood and may increase your risk of side effects.

You are encouraged to report negative side effects to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

**Please see full Prescribing Information, including Patient Information for patients.**

**Ojjaara**  
(momelotinib)

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK or licensor.  
PMUS-MMLBROC240011 November 2024  
Produced in USA.

**Ojjaara** } **GSK**  
(momelotinib)